Geron Corporation (GERN) : During the past 4 weeks, traders have been relatively bearish on Geron Corporation (GERN), hence the stock is down -29.45% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -34.61% relative to the S&P 500. The 4-week change in the price of the stock is -30.88% and the stock has fallen -34.27% in the past 1 week.
The stock has recorded a 20-day Moving Average of 28.99% and the 50-Day Moving Average is 29.8%.The 200 Day SMA reached 38.96% Geron Corporation has dropped 31.14% during the last 3-month period . Year-to-Date the stock performance stands at -61.16%.
For the current week, the company shares have a recommendation consensus of Buy. Geron Corporation (NASDAQ:GERN): stock was range-bound between the intraday low of $1.84 and the intraday high of $1.985 after having opened at $1.97 on Fridays session. The stock finally closed in the red at $1.97, a loss of -4.57%. The stock remained in the red for the whole trading day. The total traded volume was 4,199,312 shares. The stock failed to cross $1.985 in Fridays trading. The stocks closing price on Thursday was $1.88.
Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.